Programmes & Partnerships
From a purely charitable standpoint, Surgipharm actively donates products and training, and often provides subsidised medicines, supplies and logistics to several community organisations and government programmes.
From a business standpoint, we seek to involve ourselves in as many socially responsible private sector initiatives as possible. It is our belief that through such initiatives Surgipharm can make the greatest impact. This means that we are regularly partnering with other private, for profit suppliers, NGOs and government institutions.
A joint venture with i+solutions and the Dutch government to improve access to quality health care services in Uganda through the provision of a buffer stock of antiretroviral (ARV) drugs, supplied to organisations at not-for-profit prices.
An initiative with the Ugandan Ministry of Health and Medicines for Malaria Venture (MMV), a Swiss not-for-profit public-private partnership, to provide highly subsidised and repackaged artemisinin-based combination therapies (ACTs) through the private sector in four districts in eastern Uganda in order to assess whether such ACTs will have greater uptake and thus greater health impact for the poorest patients.
An innovative financing mechanism, hosted and managed by the Global Fund, designed to expand access to the most effective treatment for malaria, ACTs. Surgipharm is a first line buyer for Uganda and is working with manufacturers to avail these highly subsidised ACTs to the country.
National Injection Safety Campaign
A partnership with the Ugandan Ministry of Health, representing Becton Dickinson; working to reduce the transmission of communicable diseases through stocking and availing innovative syringes and sharps collector products through policy implementation and sensitising programmes.
Orthopaedic and Spinal Procedures
A partnership with Smith & Nephew and Medtronic focusing on the introduction and facilitation of modern orthopaedic and spinal procedures achieved through hands-on training and considerable up front investment in the requisite implants and instrumentation resulting in lower end-user costs.